The American Journal of Medicine
Volume 81, Issue 6 , Pages 962-968 , December 1986

Acute nonlymphocytic leukemia after treatment of small cell lung cancer

Received 5 November 1985 ,Accepted 10 December 1985.

References 

  1. Rosner F, Grunwald HW, Zarrabi HM. Cancer after the use of alkylating and non-alkylating cytotoxic agents in man. Cancer Surveys. 1982;1:599–612
  2. Pedersen-Bjergaard J, Philip P, Mortensen BT, et al.  Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. In: Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. 2nd ed.. Blood. 57:1981;p. 712–723
  3. Pederson-Bjergaard J, Philip P, Pederson NT, et al.  Acute nonlymphocytic leukemia, preleukemia, and acute nyeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy and survival in a total series of 55 patients. Cancer. 1984;54:452–462
  4. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65:1364–1372
  5. Pederson-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med. 1983;307:965–971
  6. Pederson-Bjergaard J, Ersboll J, Sorensen HM, et al.  Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. In: Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. 2nd ed.. Ann Intern Med. 103:1985;p. 195–200
  7. Johnson DH, Greco FA. Small cell carcinoma of the lung. CRC Crit Rev Oncol Hematol. 1986;4:303–336
  8. Shrimp W, Belzer MB. Acute leukemia after treatment of small-cell carcinoma of the lung. N Engl J Med. 1981;304:845–846
  9. Newcomer LN, Farber LR. Acute myelogeneous leukemia after successful treatment of small cell carcinoma of the lung. South Med J. 1982;75:80–81
  10. Bradley EC, Schecter GP, Matthews MJ, et al.  Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. Cancer. 1982;49:221–223
  11. Vogelzang NJ, Arthur D, Kennedy BJ. Leukemia occurring after treatment of small cell lung cancer. Cancer Treat Rep. 1982;66:1683–1684
  12. Markman M, Parvy MD, Abeloff MD. Acute leukemia following intensive therapy for small-cell carcinoma of the lung. Cancer. 1982;50:672–675
  13. Mukherji B, Yamase HT. Acute leukemia developing after intensive chemotherapy for small cell cancer of the lung. Cancer Treat Rep. 1983;67:100–101
  14. Rose VL, Kepper MD, Eichner ER, Pitha JV, Murray JL. Acute leukemia after successful chemotherapy for oat cell carcinoma. Am J Clin Pathol. 1983;79:122–124
  15. Jackson DV, Cruz JM, Woodruff R. Small cell carcinoma of the lung: rapid development of acute leukemia. NC Med J. 1983;44:475–476
  16. Volk SA, Mansour RF, Grandara DR, Redmond J. Morbidity in long-term survivors of small cell carcinoma of the lung. Cancer. 1984;54:25–27
  17. Chak LY, Sikic BI, Tucker MA, Horns RC, Cox RS. Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. J Clin Oncol. 1984;2:385–390
  18. Greco FA, Richardson RL, Snell JD, Stroup SL, Oldham RK. Small cell lung cancer: complete remission and improved survival. Am J Med. 1979;66:625–630
  19. Hande KR, Oldham RK, Fer MF, Richardson RL, Greco FA. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med. 1982;73:413–419
  20. Perez CA, Einhorn L, Oldham RK, et al.  Randomized trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation. In: A preliminary report. 2nd ed.. J Clin Oncol. 1:1984;p. 1200–1208
  21. Lowenbraun S, Birch R, Buchanan R, et al.  Combination chemotherapy in small cell lung carcinoma. In: A randomized study of two intensive regimens. 2nd ed.. Cancer. 54:1984;p. 2344–2350
  22. Groner GF, Hopwood MD, Palley NA, Sibley WL. An introduction to the CLINFO prototype data management and analysis system. In: 2nd ed.. handbook R-1541-NIH. Santa Monica, California: Rand Corporation; 1977;
  23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  24. Makuch R, Simon R. Recommendations for the analysis of the effect of treatment on the development of second malignancies. Cancer. 1979;44:250–253
  25. Surveillance, Epidemiology, and End Results: Incidence and mortality data, 1973-77. Natl Cancer Inst Monogr. 1981;57:10–186
  26. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator (publication no. 79-1649). Bethesda: National Institutes of Health; 1979;
  27. Anderson RL, Bagby GC, Richert-Boe K, Magenis RE, Koler RD. Therapy-related preleukemic syndrome. Cancer. 1981;47:1867–1871
  28. Gyger M, Forest L, Vuong TE, et al.  Therapy-induced preleukaemia in patients treated for Hodgkin's lymphoma: clinical and therapeutic relevance of sequential chromosome banding studies. Br J Haematol. 1984;58:61–69
  29. Hande KR, Desprez RM. Current perspectives in small cell lung cancer. Chest. 1984;85:669–677
  30. Morstyn G, Ihde DC, Lichter AS, et al.  Small cell lung cancer 1973–1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys. 1984;10:515–539
  31. Ellison N, Bernath A, Kane P, Porter P. Disturbing problems of success: clinical status of long-term survivors of small cell lung cancer (SCLC) (abstr). In: 2nd ed.. Proc Am Soc Clin Oncol. 1:1982;p. 149
  32. Johnson BE, Ihde DC, Bunn PA, et al.  Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. In: Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. 2nd ed.. Ann Intern Med. 103:1985;p. 430–435
  33. Harris CC. The carcinogenicity of anticancer drugs: a hazard in man. Cancer. 1976;37:1014–1023
  34. Vardiman JW, Bitler M, Golomb H. Features of therapy-related leukemia and their comparison with leukemia de novo and with the blast phase of chronic granulocytic leukemia. In:  Polliack A editors. Human leukemias. Boston: Martinus Nijhoff; 1984;p. 159–171
  35. Bennett JM, Catovsky D, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-operative Group. Br J Haematol. 1976;33:451–458
  36. In: Fourth International Workshop on Chromosomes in Leukemia. 1982. 2nd ed.. Cancer Genet Cytogenet. 11:1984;p. 251–258
  37. Sandberg AA, Abe S, Kowalczyk JR, Zedgenidzi A, Takeuchi J, Kakati S. Chromosomes and causation of human cancer and leukemia. In: Cytogenetics of leukemias complicating other diseases. 2nd ed.. Cancer Genet Cytogenet. 7:1982;p. 95–136
  38. Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB. Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood. 1979;53:695–706
  39. Sandberg AA. Application of cytogenetics in neoplastic diseases. CRC Crit Rev Clin Lab Sci. 1985;22:219–274
  40. Whang-Peng J, Bunn PA, Kao-Shan CS, et al.  A nonrandom chromosomal abnormality, de13p (14–23), in human small cell lung cancer. Cancer Genet Cytogenet. 1982;6:119–134
  41. Woods RL, Levi JA. Chemotherapy for small cell lung cancer (SCLC): a randomized study of maintenance therapy with cyclophosphamide, Adriamycin, and vincristine (CAV) after remission induction with cis-platinum (cisDDP), VP-16-213, and radiotherapy (abstr). In: 2nd ed.. Proc Am Soc Clin Oncol. 3:1984;p. 214
  42. Feld R, Evans WK, Deboer G, et al.  Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol. 1984;2:294–304
  43. Greist A, Roth B, Einhorn L, Williams SD. Cisplatin-containing chemotherapy for disseminated germ cell tumors: long term follow-up (abstr). In: 2nd ed.. Proc Am Soc Clin Oncol. 4:1985;p. 100
  44. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69:585–594
  45. Johnson DH, Wolff SN, Hainsworth JD, et al.  Extensive-stage small cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide (VP-16-213). J Clin Oncol. 1985;3:170–175

☆ This work was supported in part by National Institutes of Health Grant CA-19429 and American Cancer Society Grant JFCF-714. Dr. Johnson is a junior faculty clinical fellow of the American Cancer Society.

☆☆ A continuing medical education quiz on this article (one hour of Category 1 credit) appears on page A105 of this issue.

PII: 0002-9343(86)90388-8

The American Journal of Medicine
Volume 81, Issue 6 , Pages 962-968 , December 1986

Article Tools